Breaking News, Financial News

Financial Report: WuXi PharmaTech

Growth in the quarter was driven primarily by 28% growth in revenues for China-based Lab Services to $41.6 million, offset by an 81% decline in manufacturing services revenue.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

WuXi PharmaTech 1Q 1Q Revenues: $59.1 million (+5%) 1Q Earnings: $23.3 million (-11%) Comments: Growth in the quarter was driven primarily by 28% growth in revenues for China-based Lab Services to $41.6 million, offset by an 81% decline in manufacturing services revenue. Lab services revenue grew 33% to $56.5 million, driven by organic growth and the AppTec acquisition....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters